Apellis Pharmaceuticals (APLS) and Sobi said Friday that new data from a phase 3 study showed that Empaveli demonstrated 68% proteinuria reduction that was sustained for one year.
The study evaluated Empaveli, or pegcetacoplan, in patients with kidney diseases C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.
According to phase 3 data, patients treated with Empaveli also showed stabilization of kidney function as measured by estimated glomerular filtration rate, the companies said. The product candidate showed favorable safety and tolerability, with no new safety signals observed, the partners added.
Marketing applications for Empaveli are currently under review in Europe and the US, according to the statement.
Shares of Apellis were up more than 1% in recent trading Friday.
Price: 19.34, Change: +0.24, Percent Change: +1.26
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。